Does Wegovy Cause Gallbladder Problems?
Yes, Wegovy (semaglutide) carries a risk of gallbladder-related issues, including gallstones (cholelithiasis), inflammation (cholecystitis), and the need for gallbladder removal (cholecystectomy). These are listed in its FDA-approved prescribing information as adverse reactions observed in clinical trials and post-marketing reports.[1][2]
How Common Are These Issues?
In the STEP clinical trials for weight management (Wegovy's primary indication), gallbladder disorders occurred in:
- 4.5% of Wegovy users (2.6 mg dose) vs. 2.3% on placebo.
- Cholelithiasis specifically: 2.8% vs. 1.6%.
- Cholecystitis: 0.6% vs. 0.2%.
Rates were dose-dependent and higher with rapid weight loss, a known risk factor for gallstones regardless of the drug.[1][3]
Post-approval data from the FDA's FAERS database shows thousands of gallbladder-related reports, though causality isn't always confirmed due to confounding factors like obesity itself.[2]
Why Does This Happen?
Semaglutide slows gastric emptying and promotes significant weight loss (up to 15-20% body weight in trials), which increases bile stasis and cholesterol saturation in the gallbladder. This mirrors risks with other GLP-1 agonists like Ozempic or Mounjaro.[1][4]
What Do Patients Report?
Real-world experiences on platforms like Drugs.com and Reddit describe symptoms starting 3-12 months into treatment: upper abdominal pain, nausea, bloating, and jaundice. Some require surgery; others resolve after dose adjustment or stopping the drug. Risk factors include female sex, rapid weight loss >1.5 kg/week, and prior gallstone history.[3][5]
How Does This Compare to Other Weight Loss Drugs?
| Drug | Gallbladder Risk in Trials | Notes |
|------|----------------------------|-------|
| Wegovy (semaglutide) | 4.5% | Dose-related; tied to weight loss speed. |
| Saxenda (liraglutide) | 2-4% | Similar GLP-1 mechanism. |
| Phentermine | <1% | Less weight loss, lower risk. |
| Orlistat | 2-3% | Different mechanism (fat absorption blocker). |
GLP-1 drugs as a class show 1.5-4x higher odds vs. placebo.[4]
What Should You Do If You're Concerned?
Monitor for right-upper quadrant pain, fever, or vomiting. The label advises evaluation for gallstones if symptoms arise. No routine screening is recommended for low-risk patients, but discuss with your doctor if you have risk factors. Weight loss slows if you pause treatment.[1][2]
Are There Ongoing Studies or Updates?
Recent 2023-2024 analyses confirm the association but note most cases are mild and manageable. No black-box warning, but it's in the Warnings section. Eli Lilly's trials for tirzepatide (Zepbound) show similar 4-6% rates.[3][6]
Sources:
[1]: Wegovy Prescribing Information (FDA)
[2]: FDA Adverse Event Reporting System (FAERS) Summary
[3]: NEJM STEP Trials (2021)
[4]: JAMA Network Open GLP-1 Review (2023)
[5]: Drugs.com Wegovy Reviews
[6]: Eli Lilly Tirzepatide Label